

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

| APPLICATION NO.                    | FIL  | ING DATE   | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO.     | CONFIRMATION NO. |  |
|------------------------------------|------|------------|----------------------|-------------------------|------------------|--|
| 09/829,621 04/10/2001              |      | 4/10/2001  | Moshe Flashner-Barak | 1662/52202              | 1662/52202 7987  |  |
| 26646                              | 7590 | 08/22/2002 |                      |                         |                  |  |
| KENYON &                           |      | ON         | EXAMINER             |                         |                  |  |
| ONE BROADWAY<br>NEW YORK, NY 10004 |      |            |                      | PULLIAM                 | PULLIAM, AMY E   |  |
| ,                                  |      |            |                      | ART UNIT                | PAPER NUMBER     |  |
|                                    |      |            |                      | 1615                    |                  |  |
|                                    |      |            |                      | DATE MAILED: 08/22/2002 | 5                |  |
|                                    |      |            |                      |                         |                  |  |

Please find below and/or attached an Office communication concerning this application or proceeding.

|   |  | Application No.                    | Applicant(s)  |  |  |  |  |
|---|--|------------------------------------|---|--|--|--|--|
|   | Office Action Summer-  | 09/829,621                         | FLASHNER-BARAK, MOSHE                                     |  |  |  |  |
| Office Action Summary   |  | Examiner                           | Art Unit  |  |  |  |  |
|   | TI MAN NO DATE (A)   | Amy E Pulliam                      | 1615  |  |  |  |  |
| Period fo   | The MAILING DATE of this communication app<br>r Reply  | ears on the cover sheet with the c | correspondence address                                    |  |  |  |  |
| A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status |  |                                    |   |  |  |  |  |
| 1)⊠   | Responsive to communication(s) filed on 10 A   | pril 2001 .                        |   |  |  |  |  |
| 2a)[]   |  | s action is non-final.             |   |  |  |  |  |
| 3)  |  |                                    |   |  |  |  |  |
| Dispositi   | closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. <b>Disposition of Claims</b>   |                                    |   |  |  |  |  |
| 4)⊠ Claim(s) <u>1-65</u> is/are pending in the application.   |  |                                    |   |  |  |  |  |
| 4a) Of the above claim(s) is/are withdrawn from consideration.  |  |                                    |   |  |  |  |  |
| 5) 🗌  | Claim(s) is/are allowed.   |                                    |   |  |  |  |  |
| 6)□   | 6) Claim(s) is/are rejected.   |                                    |   |  |  |  |  |
| 7)  | Claim(s) is/are objected to.   |                                    |   |  |  |  |  |
|   | Claim(s) <u>1-65</u> are subject to restriction and/or e   | election requirement.              |   |  |  |  |  |
| · · · _   | on Papers  |                                    |   |  |  |  |  |
| 9)  The specification is objected to by the Examiner.  10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.   |  |                                    |   |  |  |  |  |
| 10)[_]  |  |                                    |   |  |  |  |  |
| 11)[] ]   | Applicant may not request that any objection to the  |                                    |   |  |  |  |  |
| /   | 11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.  If approved, corrected drawings are required in reply to this Office action. |                                    |   |  |  |  |  |
| 12) ☐ The oath or declaration is objected to by the Examiner.   |  |                                    |   |  |  |  |  |
| Priority under 35 U.S.C. §§ 119 and 120   |  |                                    |   |  |  |  |  |
| 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).   |  |                                    |   |  |  |  |  |
| a) ☐ All b) ☐ Some * c) ☐ None of:  |  |                                    |   |  |  |  |  |
| 1. ☐ Certified copies of the priority documents have been received.   |  |                                    |   |  |  |  |  |
|   | 2. Certified copies of the priority documents have been received in Application No   |                                    |   |  |  |  |  |
| Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  |  |                                    |   |  |  |  |  |
| 14)⊠ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).   |  |                                    |   |  |  |  |  |
| a) ☐ The translation of the foreign language provisional application has been received. ☐ 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.   |  |                                    |   |  |  |  |  |
| Attachment(s)   |  |                                    |   |  |  |  |  |
| 2) Notice   | e of References Cited (PTO-892)<br>e of Draftsperson's Patent Drawing Review (PTO-948)<br>nation Disclosure Statement(s) (PTO-1449) Paper No(s)                            | 5) Notice of Informal              | y (PTO-413) Paper No(s) ·<br>Patent Application (PTO-152) |  |  |  |  |
| .S. Patent and Tra  | ademark Office   | <del> </del>                       |   |  |  |  |  |

Application/Control Number: 09/829,621

Art Unit: 1615

## **DETAILED ACTION**

## Election/Restrictions

This application contains claims directed to the following patentably distinct species of the claimed invention:

A. Numerous polymers to be used in the microsphere composition, including those listed in claims 9 and 37 and those listed in claims 11 and 39. Applicant must elect one of the groupings of polymers.

B. Numerous apoptosis inducing chemotherapeutics, including cisplatin, adriamycin, butyric acid, cyclophosphamide, etoposide, amsacrine, genistein, mitoguazone, and paclitaxel. Applicant must elect one of the chemotherapeutics.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected (specifically defined polymer grouping and a specifically defined apoptosis inducing chemotherapeutic) consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the

Art Unit: 1615

limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amy E Pulliam whose telephone number is 703-308-4710. The examiner can normally be reached on Mon-Thurs 7:30-5:00, Alternate Fri 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman Page can be reached on 703-308-2927. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3592 for regular communications and 703-305-3592 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

August 20, 2002